logo

For the Inventor, By the Inventor

Roydon, United Kingdom

Helen Jane Szekeres

This inventor holds 10 USPTO granted patents and 1 published patent application and 2 EPO patents. Top assignees: Merck Sharp + Dohme Corp., Eli Lilly and Company. Active years: 2005-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Helen Jane Szekeres. Retrieved from https://idiyas.com/inventor/helen-jane-szekeres

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 10 

% Patents Active = 50.0


Average Co-Inventor Count = 4.4

ph-index = 3

Forward Citations = 18(Granted Patents)


Location History:

  • Roydon, GB (2005 - 2006)
  • Basingstoke, GB (2011)
  • Bisley, GB (2006 - 2023)

Company Filing History:

goldMedal6 out of 2,405 
 
Merck Sharp + Dohme Corp.
 patents
silverMedal4 out of 4,517 
 
Eli Lilly and Company
 patents

Years Active: 2005-2025

Loading Chart...
Loading Chart...
10 patents (USPTO):Explore Patents
1. 12344584 - KCNQ potentiators (2025-07-01),
2. 11840516 - KCNQ potentiators (2023-12-12),
3. 11208383 - KCNQ potentiators (2021-12-28),
4. 8049013 - 5- [4-(azetidin-3-yloxy)-phenyl]-2-phenyl-5H-thiazolo[5,4-C] pyridin-4-one derivatives and their use as MCH receptor antagonists (2011-11-01),
5. 7271191 - Pyrazole derivatives as gamma-secretase inhibitors useful in the treatment of Alzheimer's disease (2007-09-18),
6. 7153868 - N-(3-(4-substituted-1-piperidinyl)-1-phenylpropyl) substituted sulfonamides as NK-3 receptor antagonists (2006-12-26),
7. 7094777 - [object Object] (2006-08-22),
8. 6936608 - Imidazo-triazine derivatives as ligands for GABA receptors (2005-08-30),
9. 6900215 - Imidazo-pyrimidine derivatives as ligands for gaba receptors (2005-05-31),
10. 6900209 - Nitrogen substituted 1,2,4-triazolo[3,4-a]phthalazine derivatives for enhancing cognition (2005-05-31),

Title: The Innovations of Helen Jane Szekeres: A Pioneer in Neurological Treatments

Introduction

Helen Jane Szekeres is an esteemed inventor based in Roydon, GB, known for her significant contributions to the field of medicinal chemistry and neurology. With a remarkable portfolio of ten patents, Helen has dedicated her career to advancing treatment options for neurological diseases, particularly those impacting motor neuron functionality.

Latest Patents

Her latest patents focus on KCNQ potentiators, which are small molecule potentiators targeting potassium channels, specifically Kv7 channels. These innovative compounds hold the potential to treat Amyotrophic Lateral Sclerosis and various other neurological conditions linked to motor neuron excitability changes. These conditions include an array of disorders such as primary lateral sclerosis, pseudobulbar palsy, progressive bulbar palsy, progressive muscular atrophy, and epilepsy.

Career Highlights

Helen has garnered invaluable experience through her work with prominent companies, including Merck Sharp & Dohme Corporation and Eli Lilly and Company. Her career reflects her commitment to improving patient outcomes and expanding the understanding of neurological diseases, marking her as a leader in her field.

Collaborations

Helen has collaborated with notable professionals in her industry, including Mark Stewart Chambers and Philip Jones. These collaborations have contributed to her innovative approach and the successful advancement of her research and development efforts.

Conclusion

Helen Jane Szekeres stands out as a visionary inventor whose work continues to inspire advancements in the treatment of serious neurological conditions. Her dedication to research and her innovative spirit play a crucial role in shaping the future of neurological therapies.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…